High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: True or false? [2]

Breast Journal

Volumn 12, Issue 5, 2006, Pages 499-501

  Saatee, Siavosh ^a   Afrakhteh, Maryam ^a   Sadrolhefazi, Behbood ^a  

^a Shahid Beheshti University ^*  (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IRAN; LETTER; MAJOR CLINICAL STUDY; PREVALENCE; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IRAN; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33748358570     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2006.00315.x     Document Type: Letter

References (14)

1. Burstein JH. The distinctive nature of HER-2 positive breast cancers. N Engl J Med 2005;353:1652-54.
2. Coussens L, Yang-Feng TC, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-39.
3. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58.
4. Winer EP, Carey LA, Dowsett M, Tripathy D. Beyond anatomic staging: are we ready to take the leap to molecular classification? In: Perry MC, ed. Proceedings of 41st American Society of Clinical Oncology Annual Meeting; 2005. Alexandria, VA: American Society of Clinical Oncology, 2005:46-59.
5. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multicenter study. Asian Pac J Cancer Prev 2004;5:24-27.
6. Harirchi I, Ghaemmaghami F, Karbakhsh M, Moghimi R, Mazaherie H. Patient delay in women presenting with advanced breast cancer: an Iranian study. Public Health 2005;119:885-91.
7. Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-95.
8. Huang CS, Chen YC, Wang M, et al. HER-2/neu overexpression in Chinese breast cancers: correlation with other prognostic factors. J Formos Med Assoc 1995;94:660-65.
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug administration approved scoring system. Clin Oncol 1999;17:1983-87.
10. Vogal CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
11. Lan C, Liu JM, Liu TW, et al. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol 2005;124:97-102.
12. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
13. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-8.
14. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of HER-2/neu, steroid receptors (ER and PR), Ki67 and P53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005;25:1719-24.